425: Alumis and ACELYRIN Reaffirm Commitment to All-Stock Merger, Citing Strategic and Financial Benefits

Alumis and ACELYRIN reaffirm their commitment to merge in an all-stock transaction, creating a leading clinical-stage biopharma company focused on immune-mediated diseases.

Summary

• Alumis and ACELYRIN have reaffirmed their commitment to merge in an all-stock transaction.
• The merger aims to create a leading clinical-stage biopharma company focused on immune-mediated diseases.
• The combined company will have a stronger financial position to support a diverse pipeline with multiple catalysts.
• The pro forma cash position is expected to be approximately $737 million as of December 31, 2024.
• This cash is expected to fund the pipeline through key data readouts and cover operating expenses into 2027.
• The transaction is expected to close in the second quarter of 2025, pending stockholder approval and customary closing conditions.
• The combined company will have a diversified portfolio of late-stage clinical assets for validated targets in multi-billion dollar markets.
• Key programs include ESK-001 for psoriasis and lupus, lonigutamab for thyroid eye disease, and A-005 for multiple sclerosis.

Sentiment

Score: 7

Explanation: The document expresses a positive outlook on the merger, highlighting the strategic and financial benefits. The sentiment is moderately positive due to the forward-looking nature of the statements and the inherent risks associated with mergers and drug development.

Positives

• The merger creates a company with a stronger financial position and a diverse pipeline.
• The combined company is expected to have sufficient cash to fund operations into 2027.
• The merger is expected to unlock value for current and future investors.
• The combined company will have a diversified portfolio of late-stage clinical assets for validated targets in multi-billion dollar markets.

Risks

• The merger may not be completed in a timely manner or at all.
• Required approvals may not be received.
• The announcement of the merger may negatively impact the companies' ability to retain key personnel and maintain relationships.
• The anticipated benefits and synergies of the merger may not be fully realized or may take longer to realize than expected.
• There are risks related to the value of Alumis securities to be issued in the proposed transaction.
• Integration of the proposed transaction post-closing may not occur as anticipated.

Future Outlook

The combined company expects to advance its pipeline through multiple key data readouts and fund operating expenses and capital expenditure requirements into 2027.

Management Comments

• Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, Alumis and ACELYRIN together will advance exciting breakthroughs for patients and drive long-term value for stockholders through the creation of a leading clinical stage biopharma company in immune-mediated diseases.
• Mina Kim, Chief Executive Officer of ACELYRIN, stated that the all-stock transaction with Alumis maximizes long-term value for ACELYRIN stockholders.

Industry Context

The merger reflects a trend in the biopharmaceutical industry to consolidate assets and resources to develop and commercialize innovative therapies, particularly in the competitive field of immune-mediated diseases.

Comparison to Industry Standards

• The combined company's focus on immune-mediated diseases aligns with the strategies of companies like Bristol Myers Squibb and AbbVie, which have significant portfolios in this area.
• The pro forma cash position of $737 million is substantial for a clinical-stage company, providing a competitive advantage in advancing its pipeline compared to peers with less funding.
• The pipeline assets, including ESK-001, lonigutamab, and A-005, target validated pathways and indications, similar to the approach of companies like UCB and Roche in developing targeted therapies.

Stakeholder Impact

• The merger is expected to benefit stockholders through long-term value creation.
• Patients are expected to benefit from the development of life-changing medicines.
• Employees of both companies may be affected by the integration process.

Next Steps

• Alumis expects to publicly file the S-4 and begin mailing of the proxy statement related to the transaction promptly following completion of the fiscal year 2024 audits and filing of Annual Reports on Form 10-K by each of Alumis and ACELYRIN.
• Alumis and ACELYRIN will file an investor presentation with the Securities and Exchange Commission with background information regarding ACELYRINs strategic review process, which will be available this week.
• The transaction is expected to close in the second quarter of 2025, subject to approval by the stockholders of both companies and satisfaction of other customary closing conditions.

Key Dates